SFEBES2007 Oral Communications Clinical and translational endocrinology (8 abstracts)
Effect of once-yearly infusion of Zoledronic acid 5 mg in postmenopausal women with osteoporosis
Richard Eastell 1 , Dennis Black 2 , Jane Cauley 3 , Felicia Cosman 4 , Steve Cummings 2 , Pierre Delmas 5 , Erik Fink Eriksen 6 , William Fraser 7 , Trisha Hue 2 , Peter Lakatos 8 , Ping-Chung Leung 9 , Zulema Man 10 , Alastair McLellan 11 , Peter Mesenbrink 15 , David M Reid 12 , Ian Reid 13 & Steven Boonen 14
1Northern General Hospital, Sheffield, South Yorkshire, United Kingdom; 2University of California at San Francisco, San Francisco, CA, United States; 3University of Pittsburgh, Pittsburgh, PA, United States; &br;4Helen Hayes Hospital, West Haverstraw, NY, United States; 5University Claude Bernard, Lyon, France; 6Novartis Pharma AG, Basel, Switzerland; 7University of Liverpool, Liverpool, United Kingdom; 8Semmelweis University, Budapest, Hungary; 9Chinese University of Hong Kong, Hong Kong, China; 10Centro Tiempo, Buenos Aires, Argentina; 11Gardner Institute, Western Infirmary, Glasgow, United Kingdom; 12Medical School Foresthill, Aberdeen, United Kingdom; 13University of Auckland, &br;Auckland, New Zealand; 14Leuvan University, Leuvan, Belgium; 15Novartis Pharma AG, East Hanover, NJ, United States. All Authors for the HORIZON Pivotal Fracture Trial (PFT) Research Group, San Francisco, CA, United States.
Objectives and methods: The HORIZON-PFT is a multinational, 3-year, randomized, double-blind, placebo-controlled trial evaluating the potential of once-yearly zoledronic acid (ZOL) 5 mg, infused over 15 minutes, to decrease risk of fracture in 7736 postmenopausal osteoporotic women 65–89 years of age.
Results: Treatment with ZOL 5 mg resulted in significant relative risk reductions in morphometric vertebral fracture of 70% vs PBO (3.8% vs 12.8%; 95% CI [62%, 76%]) and in hip fracture of 41% vs PBO (1.4% vs 2.5%; 95% CI [17%, 58%]). Secondary endpoints, non-vertebral (excluding finger, toe, and facial), clinical vertebral, and any clinical fracture (including non-vertebral, hip, and clinical vertebral), were significantly reduced by 25%, 77%, and 33% (all P<.001), respectively. Bone mineral density increased significantly in ZOL vs PBO at total hip (6.0%), lumbar spine (6.9%) and femoral neck (5.0%) (P<.0001). While transient increases in serum creatinine ≥0.5 mg/dL over pre-infusion levels were seen in a small fraction (1.3%) of patients in the ZOL 5 mg group; no cumulative impact on renal function was demonstrable. Hypocalcemia (serum calcium <2.075 mmol/L) was observed in 2.3% of patients. Virtually all events occurred after the first infusion of ZOL, and all cases were asymptomatic and transient. Adverse events occurring ≤3 days after infusion were more frequent after first infusion (44.7% ZOL vs 14.7% PBO) but declined markedly on subsequent infusions. There were more atrial fibrillation serious adverse events in ZOL vs PBO (1.3% vs 0.5%). Two cases of osteonecrosis of the jaw (1 in PBO, 1 in ZOL) were confirmed with adjudication; both cases resolved with antibiotic therapy and limited debridement.
Conclusions: Once-yearly infusion of ZOL 5 mg over 3 years achieves a highly significant decrease in vertebral, hip, and other fracture risk and is generally safe and well tolerated.
Article tools
My recent searches
My recently viewed abstracts
Authors
Endocrine Abstracts
ISSN 1470-3947 (print) | ISSN 1479-6848 (online)
© Bioscientifica 2024 |
Privacy policy |
Cookie settings
BiosciAbstracts
Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.
Find out more